The Biograph Vision.X positron emission tomography/computed tomography (PET/CT) reportedly offers an industry-leading time of flight (TOF) and detector technology that facilitates the diagnosis of smaller lesions.
Offering an array of technological advantages with positron emission tomography/computed tomography (PET/CT), the Biograph Vision.X™ system has garnered 510(k) clearance from the Food and Drug Administration (FDA).
The Biograph Vision.X features a time of flight (TOF) of 178 picoseconds and Optiso Ultra Dynamic Range (UDR) detector technology, according to Siemens Healthineers, the manufacturer of the device. Utilizing 3.2 x 3.2 mm lutetium oxyorthosilicate (LSO) crystal elements that provide enhanced spatial resolution in comparison to larger crystals, the company noted the UDR technology enables 48 mm3 volumetric resolution and temporal resolution of 178 ps.
“The Biograph Vision.X’s record-shattering, ultrafast time of flight delivers an image resolution that allows even the smallest lesions to rise above the noise,” said James Williams, Ph.D., the head of Siemens Healthineers Molecular Imaging. “This extremely high level of resolution can help physicians detect small lesions and provide patients with a precise diagnosis.”
In order to optimize radiology workflow, Siemens Healthineers said the system’s built-in AIDAN intelligent imaging platform has a foundation of over 700 patents in machine learning and deep learning applications. The company added that the optional FlowMotion™ AI feature for the Biograph Vision.X device enables clinicians to personalize image acquisition with one click via a combination of anatomical AI and continuous bed motion.
CT-Based Fractional Flow Reserve Analysis Improves Five-Year Outcomes After Major Vascular Surgery
May 24th 2024For patients with no history of coronary artery disease (CAD), new research shows the use of CT-derived fractional flow reserve (FFR-CT) guided revascularizations after elective vascular surgery reduced myocardial infarction and all-cause death by 20 percent in comparison to standard care.
Study: PSMA PET/CT Agent May Rule Out csPCa in 93 Percent of PI-RADS 3 Lesions
May 22nd 2024New prospective research examining the utility of 18F-PSMA-1007 PET/CT revealed comparable sensitivity to mpMRI for detecting clinically significant prostate cancer and a 17 percent higher specificity rate.